Company / Operating Cash Flow
IDEAYA Biosciences, Inc. Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$71.1M
FY2025
5-year range
-$247.6M / $55.5M
FY2021-FY2025
Trend
+71.3%
vs FY2024
Sector context
#108 of 216
Health Care
What the data says
At -$71M, IDEAYA Biosciences, Inc.'s operating cash flow ranks #108 of 216 in the Health Care sector. Operating Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$71M.
Based on SEC 10-K filings.
-$71M in FY2025.
Improved from -$115M to -$71M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#108 of 216 in Health CareTop 50% of 216This company -$71.1M Sector average $659.0M
▼
-110.8% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 71.3% year-over-year.
- Ranks #108 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2022.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 4.55 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$71.1M | +71.3% |
| FY2024 | -$247.6M | -114.9% |
| FY2023 | -$115.2M | -307.7% |
| FY2022 | $55.5M | +241.1% |
| FY2021 | -$39.3M | -42.3% |
| FY2020 | -$27.6M | +29.7% |
| FY2019 | -$39.3M | -42.3% |
| FY2018 | -$27.6M | -125.9% |
| FY2017 | -$12.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026